Clinical Trials
4 trialsNCT03707938 2025-11-03
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04227028 2025-09-16
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT04005144 2022-10-17
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
University of California, San Francisco
Phase 1 Terminated